On October 18, 2022 Nerviano Medical Sciences Srl (Company), a member of NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, reported that data from the Company’s Phase I/II clinical study of NMS-01940153E in Hepatocellular carcinoma (HCC) will be reported in an oral presentation by Dr. Maria Reig at the upcoming EORTC-NCI-AACR (Free EORTC-NCI-AACR Whitepaper) Symposium on Molecular Targets and Cancer Therapeutics (ENA 2022) which will be held October 26-28, 2022 at the CCIB in Barcelona (Press release, Nerviano Medical Sciences, OCT 18, 2022, View Source [SID1234623259]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The data are embargoed until the day of the presentation. A copy of the oral presentation will be available at www.nervianoms.com following presentation at the meeting.
About NMS-01940153E (NMS-153)
Primary liver cancer is the sixth most common neoplasm and among the leading cause of cancer-related death worldwide. HCC constitutes 80-90% of all primary liver cancers. Its incidence is increasing and will soon surpass one million annual cases worldwide. Most HCC cases are diagnosed at advanced stages and despite the recent approval of new therapeutic agents such as checkpoint inhibitors, there is a high unmet medical need.
NMS-153 is a highly potent and selective inhibitor of the MPS1 kinase, which is a mitotic regulator frequently overexpressed and activated in cancer. NMS-153 showed a broad preclinical activity in different tumor types, including HCC.
MPSA-153-001 is a Phase I/II study of NMS-153 administered as single agent in treatment experienced, unresectable HCC patients. The trial is currently open for enrollment
20221014-MPS1-ENA2022-Final